An experimental melanoma treatment has shown promising results in combating the disease.
The experimental melanoma treatment comes from Merck (MRK) and is currently identified as MK-3475. Results from a study that involved MK-3475 included a one-year survival rate of 69%. 34% of patients also saw tumors shrink. The study included 411 melanoma patients, reports TheStreet.com.
“It’s a completely different world for patients with metastatic melanoma, to talk about the majority of patients being alive for years rather than weeks or months,” Dr. Jedd D. Wolchok, a melanoma specialist, told The New York Times.
MK-3475 is part of a new class of drugs that work to stop cancer cells from hiding from the immune system. The study conducted was only in phase one, but the data that came from it showed researchers that they were onto something, TheStreet.com notes.